Company intelligence / Profile preview

Hainan Herui Pharmaceutical

Haikou, Hainan, China

Ownership: Private
Development stage: Commercial

Overview

Hainan Herui Pharmaceutical is a Chinese pharmaceutical company focused on the development and manufacturing of generic drugs. Recent clinical activity includes bioequivalence studies for tacrolimus capsules compared to Astellas' Prograf®, as well as programs involving ibuprofen for fever. The company appears to be active in the generic small molecule space with a focus on regulatory approval through bioequivalence trials rather than novel drug discovery.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hainan Herui Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hainan Herui Pharmaceutical.

Explore the full profile